Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announces its financial results ...

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Canopy Growth (CGC) stock drops 15% in premarket after the company posted wider Q3 loss due to revenue and gross margin declines. Read more here.

Canopy Growth (CGC) delivered earnings and revenue surprises of -58.33% and 12.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Investorideas , a go-to platform for big investing ideas, including cannabis stocks reports on trading for Canopy Growth Corporation (TSX: WEED ) (N ...

Reports Q3 revenue C$74.8M vs. C$78.5M last year. “Canopy Growth’s (CGC) third quarter highlights that our business has the right ingredients ...

Announced its financial results for the third fiscal quarter ended December 31, 2024. Net revenue proved $74.7 Million, while its net loss for the year came in at $121.9 Million. Canopy Growth ...

The Smiths Falls, Ontario-based cannabis company posted a narrowed net loss of 121.9 million Canadian dollars ($85.2 million), or C$1.11 a share, for the three months ended Dec. 31, compared with a ...

Canadian cannabis producer cuts debt load and shows revenue growth in key segments while pushing ahead with U.S. expansion.

Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year Record quarter for Canada medical cannabis with net revenue increasing 16%; international ...